The Good, the Bad and the Ugly: Showcasing Contract Research  

Presentations are only available to member companies (Upgrade)
	Andrew Tamworth, Business Development Director, Giles Insurance Brokers (What Happens to Risk in an Outsourced Enviroment)
	Kristina Kurz, Ph.D., VP Business Development, Evotec (UK) Ltd (What Will a CRO Become When it Grows Up)

Speakers Include:

Kristina Kurz, Ph.D., VP Business Development, Evotec (UK) Ltd
Prof Derek Terrar, Director, Oxford Cardiac Pharmacology Ltd
Andrew Tamworth, ACII, Business Development Director, Giles Insurance Brokers (Life Sciences)
one further t.b.a.

Programme:

Registration: 6.00 - 6.30pm

Talks: 6.30 - 7.00pm

Break for Networking with food and refreshments: 7.00pm - 7.40pm

Talks: 7.40 - 8.20pm

Networking Reception: 8.20pm - 9.30pm

Talks will be 20 minutes per speaker plus Q&A, with a brief 10 minute talk from Giles Insurance

How to register for the July 24th BioTuesday:
Contact Susan Kerry (OBN) on susan.kerry@oxfordshirebioscience.net including the delegate name, job title, email or phone 01865 483670 to reserve your place at this event, or register online. As usual the meetings are free for delegates from biotech and healthcare companies, VCs and Business Angels, Academics, and ??50 + VAT to attend for everybody else.  There is sufficient free car parking at the venue.

Andrew Tamworth, Director of Business Development at our sponsors Giles Insurance who are also sponsoring this BioTuesday will be giving a talk entitled 'What happens to risk in an outsourced environment?'

====

Kristina Kurz, Ph.D., VP Business Development, Evotec (UK) Ltd

Biography - Kristina Kurz

Kristina Kurz joined Evotec as VP Business Development in January 2005. After two years looking after Evotec???s discovery services business in California Kristina relocated to the UK and now is responsible for clients in Germany, Switzerland and Austria. Prior to Evotec Kristina worked for the Californian software start-up company Sertanty where she established the commercial infrastructure and with Thieme Medical Publishers in New York where she was responsible for the commercial launch of electronic journals and scientific databases. Kristina holds a PH.D. in organic chemistry from the University of Frankfurt/Germany followed by a postdoc in molecular biology at Yale University in New Haven/CT.

Evotec is a leader in the discovery and development of novel small molecule drugs. Through its contract research partnerships and proprietary projects, Evotec is providing the highest quality research results to its partners in the pharmaceutical and biotechnology industries. In contract research, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide by providing high quality, innovative and integrated solutions from drug target to clinic through an unmatched range of capabilities. In proprietary projects, Evotec specialises in finding new treatments for diseases of the central nervous system (CNS).

Prof Derek Terrar, Director, Oxford Cardiac Pharmacology Ltd

Company Profile - OCP Ltd

Oxford Cardiac Pharmacology Limited (OCP Ltd) provides novel methods for assessing the cardiac risk of new drugs.

There are a number of important reasons why cardiac risk should be assessed for any new drug whatever its intended target in the body.  Firstly, it would be unethical to give a new compound to healthy volunteers without having assessed this risk; secondly, regulatory authorities in the USA, Europe and Japan insist that this is done; and thirdly it makes good commercial sense to reduce costs by reducing development failures and product withdrawals.

Most pharmaceutical and biotech companies out-source this specialist toxicity testing and the few that have some in-house capabilities often need to access external expertise. OCP works in partnership with its clients to provide a tailored package of service delivery and consulting to complement each partner???s capabilities and needs.  We are at the forefront of development of new techniques to assess cardiac risk and offer our clients the benefits of this specialist knowledge.

Clients are taking a more strategic approach to out-sourcing to reduce development time and cost.  In response we are developing partnerships with other organisations to help clients achieve these goals.

Through our unique specialist knowledge OCP will continue to be at the forefront of developments in the understanding of cardiac toxicity.  The company will develop and grow to satisfy customers??? business and out-sourcing needs.

Biography - Prof Derek Terrar

Prof Derek Terrar is the Founder and Director of Research at Oxford Cardiac Pharmacology Ltd (OCP) and Professor of Cardiac Electrophysiology at Oxford University. He is one of the world???s leading authorities on the testing of the influence of drugs on cardiac muscle. He acts as an advisor to a number of companies and works closely with OCP???s clients to develop research and testing strategies.

Prof Terrar also carries out world leading research providing new insights concerning the origin and regulation of pacemaker activity of the sino-atrial node, and on the actions of novel inotropic and antiarrhythmic drugs that are based on newly discovered endogenous compounds, including cADP-ribose and related compounds. He graduated in Zoology with an interest in biophysics at University College London and obtained his PhD in the Pharmacology Department at UCL. His work on cardiac myocytes was initiated at The Middlesex Hospital and has continued at Oxford since 1984.

Andrew Tamworth ACII, Business Development Director, Giles Insurance Brokers Ltd - Biography

Andrew is a Chartered Insurance Practitioner with more than 20 years experience in the insurance industry.

Joining Miller???s life science team in 2002 and moving to Giles with its acquisition in January of this year, he now heads up business development for Giles??? life science practice.

Giles Insurance Brokers Ltd are the leading provider of insurance broking and consultancy services to the life science sector, acting for more than 200 clients ranging from university spin outs to main market listed companies.  Its wide ranging experience in the sector is testified by the endorsements of Oxfordshire Bioscience Network (OBN) and the UK Bio Industry Association (BIA).

Giles provides a complete service to its clients across a range of insurance areas including assessment of insurable risk exposures and insurance programme design, across a range of insurance classes. 

Areas of expertise include: property (whether physical or intellectual), interruption of R&D operations (including supply chain dependence); global clinical trial programmes and liability cover for the company and its directors & officers (including those relating to employers, general public, products, errors & omissions / professional indemnity and medical malpractice).